Ondansetron (Zofran) IV: Drug Safety Communication - QT prolongation

32 mg single intravenous dose may affect the electrical activity of the heart, which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes.